fosamprenavir


Also found in: Medical, Wikipedia.
Related to fosamprenavir: ritonavir
Translations

fosamprenavir

n fosamprenavir m
References in periodicals archive ?
High viral load, previous fosamprenavir use and more recent HIV diagnosis correlate with darunavir failure in salvage therapy in Sao Paulo, Brazil.
Atazanavir (Reyataz[R]), darunavir (Prezista[R]), fosamprenavir (Lexiva[R], Telzir[R]), indinavir (Crixivan[R]), lopinavir and ritonavir combination (Kaletra[R]), nelfinavir (Viracept[R]), saquinavir (Invirase[R], Fortovase[R]), and tipranavir (Aptivus[R]) are PIs (AIDSinfo, 2016; FDA, 2016).
Contract award notice: Medicamento: Abacavir/Lamivudina, Fosamprenavir, Zidovudina/Abacavir/Lamivudina.
20) This University of Sao Paulo group gives the second-generation PIs--ritonavir-boosted lopinavir, amprenavir, fosamprenavir, and tipranavir--the worst dyslipidemia marks in their Table 2 summary: three up-arrows indicating the greatest likelihood of spawning dyslipidemia.
Co-administration of moderate (diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil) or strong (eg, ketoconazole, clarithromycin, nefazodone, ritonavir) CYP3A4 inhibitors increases the concentration of flibanserin.
The PIs used were nelfinavir until 2007, saquinavir, fosamprenavir, lopinavir, atazanavir and, from 2009, darunavir.
Moderate CYP3A4 inhibitors include amprenavir, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, and grapefruit juice.
Las mutaciones I50V e I54L incrementan la susceptibilidad a tripanavir (TPV), N88S incrementa la susceptibilidad a fosamprenavir y L76V incrementa la susceptibilidad a atazanavir, saquinavir y tripanavir (42); mientras que V82A/T/F/S y I84V estan asociados a resistencia a todos los inhibidores de proteasa, resaltando por ser mutaciones con un alto grado de polimorfismo (37).
The only protease inhibitor (PI) mutation observed --M46I--causes intermediate resistance to nelfinavir, with a potential for low-level resistance to ritonavir-boosted doses of atazanavir, fosamprenavir, indinavir, and lopinavir.
FDA-Approved Antiretroviral Agents Nucleoside RTIs Nonnucleoside RTIs Protease inhibitors abacavir (ABC) delavirdine (DLV) atazanavir (ATV) didanosine (ddl) efavirenz (EFZ) darunavir (DRV) emtricitabine (FTC) etravirine (ETV) fosamprenavir (Fos-APV) lamivudine (3TC) nevirapine (NVP) indinavir (IDV) stavudine (d4T) lopinavir/r (LPV/r) zidovudine (ZDV) nelfinavir (NFV) ritonavir (RTV) saquinavir (SQV) tipranavir (TPV) Nucleotide RTI Integrase inhibitor Fusion inhibitor tenofovir DF (TDF) raltegravir (RAL) enfuvirtide (T-20) CCR5 antagonist maraviroc (MVC) Notes: Six fixed-dose combinations are approved by the Food and Drug Administration.
The 2008 IAS-USA guidelines (8) for initial antiretroviral therapy recommend either of two basic three-drug regimens: efavirenz plus two NRTIs, or a ritonavir-boosted protease inhibitor (lopinavir, atazanavir, fosamprenavir, darunavir or saquinavir) plus two NRTIs.
En el tratamiento para la infeccion por VIH, los IP tales como el lopinavir, el saquinavir y el fosamprenavir pueden inducir el desarrollo de dislipidemia con predominio del aumento de trigliceridos y LDL-c (25, 26) A su vez, el atazanavir, no causa ningun cambio desfavorable de lipidos (28).